Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis-Reference-Cited by-同舟云学术

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Published:2021-08-24 Issue:18 Volume:10 Page:6336-6343
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Botton Stéphane¹^ORCID,Brandwein Joseph M.²^ORCID,Wei Andrew H.³,Pigneux Arnaud⁴,Quesnel Bruno⁵,Thomas Xavier⁶,Legrand Ollivier⁷,Recher Christian⁸,Chantepie Sylvain⁹,Hunault‐Berger Mathilde¹⁰,Boissel Nicolas¹¹,Nehme Salem A.¹²,Frattini Mark G.¹³,Tosolini Alessandra¹³,Marion‐Gallois Roland¹³,Wang Jixian J.¹³,Cameron Chris¹⁴,Siddiqui Muhaimen¹⁴,Hutton Brian¹⁵,Milkovich Gary¹⁶,Stein Eytan M.¹⁷

Affiliation:

1. Departement d'hematologie Institut Gustave Roussy Villejuif France

2. University of Alberta Edmonton Alberta Canada

3. Alfred Hospital and Monash University Melbourne Australia

4. CHU Bordeaux Hôpital du Haut Lévêque Bordeaux France

5. CHU Lille Lille France

6. Centre Hospitalier Lyon Sud Pierre Bénite France

7. APHP Hôpital Saint‐Antoine Paris France

8. CHU de Toulouse Université de Toulouse III Paul Sabatier Toulouse France

9. CHU de Caen Caen France

10. CHU Angers Angers France

11. Hôpital Saint‐Louis Paris France

12. Celgene International, a Bristol Myers Squibb Company Boudry Switzerland

13. Bristol Myers Squibb Summit New Jersey USA

14. Cornerstone Research Group Burlington Ontario Canada

15. Ottawa Hospital Research Institute Ottawa Ontario Canada

16. RJM Group LLC Crown Point Indiana USA

17. Memorial Sloan Kettering Cancer Center New York New York USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4182

Reference35 articles.

1. Acute Myeloid Leukemia

2. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’

3. Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia

4. Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia

5. Cancer Research UK.Acute myeloid leukaemia (AML) incidence statistics.2015. Accessed May 2018.http://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/leukaemia‐aml/incidence

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers;JAMA Oncology;2024-08-29

2. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells;Biomedicines;2023-12-07

3. Evaluating the Performance of High-Dimensional Propensity Scores Compared with Standard Propensity Scores for Comparing Antihypertensive Therapies in the CPRD GOLD Database;Cardiology and Therapy;2023-05-05

4. Targeted therapy;Medicines for Cancer;2023

5. Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapy;Frontiers in Oncology;2022-10-03